NASDAQ:HRTX

Heron Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy HRTX

*Your capital is at risk

$0.447

-0.0032 (-0.711%)

At Close: Jun 03, 2026

Heron Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 14.3M and sold 94.61K HRTX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	14.3M shares
● Sell	94.61K shares
99% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 06, 2026 Buy	Restricted Stock Units M-Exempt	Hensley Mark Earl Chief Operating Officer	C-Suite Officer	125 000 Value: $163.8K
May 06, 2026 Buy	Common Stock M-Exempt	Hensley Mark Earl Chief Operating Officer	C-Suite Officer	125 000 Value: $163.8K
Apr 30, 2026 Buy	Restricted Stock Units M-Exempt	Collard Craig A Chief Executive Officer	CEO / President	34 789 Value: $41.7K
Apr 30, 2026 Buy	Common Stock M-Exempt	Collard Craig A Chief Executive Officer	CEO / President	34 789 Value: $41.7K
Apr 30, 2026 Buy	Restricted Stock Units M-Exempt	Duarte Ira EVP, Chief Financial Officer	C-Suite Officer	11 694 Value: $14.0K
Apr 30, 2026 Buy	Restricted Stock Units M-Exempt	Duarte Ira EVP, Chief Financial Officer	C-Suite Officer	13 535 Value: $16.2K
Apr 30, 2026 Buy	Common Stock M-Exempt	Duarte Ira EVP, Chief Financial Officer	C-Suite Officer	13 535 Value: $16.2K
Apr 30, 2026 Buy	Restricted Stock Units M-Exempt	Hensley Mark Earl Chief Operating Officer	C-Suite Officer	11 770 Value: $14.1K
Apr 30, 2026 Buy	Common Stock M-Exempt	Hensley Mark Earl Chief Operating Officer	C-Suite Officer	11 770 Value: $14.1K
Apr 30, 2026 Buy	Common Stock M-Exempt	Forbes William P EVP, Chief Development Officer	Officer	11 770 Value: $14.1K
Apr 30, 2026 Buy	Common Stock M-Exempt	Forbes William P EVP, Chief Development Officer	Officer	11 694 Value: $14.0K
Apr 30, 2026 Buy	Restricted Stock Units M-Exempt	Forbes William P EVP, Chief Development Officer	Officer	11 770 Value: $14.1K
Apr 30, 2026 Buy	Restricted Stock Units M-Exempt	Forbes William P EVP, Chief Development Officer	Officer	11 694 Value: $14.0K
Apr 30, 2026 Buy	Common Stock M-Exempt	Duarte Ira EVP, Chief Financial Officer	C-Suite Officer	11 694 Value: $14.0K
Apr 30, 2026 Buy	Common Stock M-Exempt	Collard Craig A Chief Executive Officer	CEO / President	50 021 Value: $60.0K
Apr 30, 2026 Buy	Restricted Stock Units M-Exempt	Collard Craig A Chief Executive Officer	CEO / President	50 021 Value: $60.0K
Apr 19, 2026 Buy	Restricted Stock Units M-Exempt	Duarte Ira EVP, Chief Financial Officer	C-Suite Officer	3 874 Value: $2K
Apr 19, 2026 Buy	Common Stock M-Exempt	Duarte Ira EVP, Chief Financial Officer	C-Suite Officer	3 874 Value: $2K
Apr 19, 2026 Buy	Restricted Stock Units M-Exempt	Collard Craig A Chief Executive Officer	CEO / President	13 797 Value: $6K
Apr 19, 2026 Buy	Common Stock M-Exempt	Collard Craig A Chief Executive Officer	CEO / President	13 797 Value: $6K
Apr 19, 2026 Buy	Restricted Stock Units M-Exempt	Forbes William P EVP, Chief Development Officer	Officer	3 874 Value: $2K
Apr 19, 2026 Buy	Common Stock M-Exempt	Forbes William P EVP, Chief Development Officer	Officer	3 874 Value: $2K
Apr 03, 2026 Buy	Common Stock M-Exempt	Collard Craig A Chief Executive Officer	CEO / President	62 500 Value: $27.9K
Apr 03, 2026 Buy	Restricted Stock Units M-Exempt	Collard Craig A Chief Executive Officer	CEO / President	62 500 Value: $27.9K
Jan 31, 2026 Buy	Common Stock M-Exempt	Duarte Ira EVP, Chief Financial Officer	C-Suite Officer	11 695 Value: $5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT HERON THERAPEUTICS

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acut...

Read Full Profile Here